Resistance related metabolic pathways for drug target identification in Mycobacterium tuberculosis

BackgroundIncreasing resistance to anti-tuberculosis drugs has driven the need for developing new drugs. Resources such as the tropical disease research (TDR) target database and AssessDrugTarget can help to prioritize putative drug targets. Hower, these resources do not necessarily map to metabolic pathways and the targets are not involved in dormancy. In this study, we specifically identify drug resistance pathways to allow known drug resistant mutations in one target to be offset by inhibiting another enzyme of the same metabolic pathway. One of the putative targets, Rv1712, was analysed by modelling its three dimensional structure and docking potential inhibitors.ResultsWe mapped 18 TB drug resistance gene products to 15 metabolic pathways critical for mycobacterial growth and latent TB by screening publicly available microarray data. Nine putative targets, Rv1712, Rv2984, Rv2194, Rv1311, Rv1305, Rv2195, Rv1622c, Rv1456c and Rv2421c, were found to be essential, to lack a close human homolog, and to share >67 % sequence identity and >87 % query coverage with mycobacterial orthologs. A structural model was generated for Rv1712, subjected to molecular dynamic simulation, and identified 10 compounds with affinities better than that for the ligand cytidine-5′-monophosphate (C5P). Each compound formed more interactions with the protein than C5P.ConclusionsWe focused on metabolic pathways associated with bacterial drug resistance and proteins unique to pathogenic bacteria to identify novel putative drug targets. The ten compounds identified in this study should be considered for experimental studies to validate their potential as inhibitors of Rv1712.

[1]  Katrin Stierand,et al.  PoseView -- molecular interaction patterns at a glance , 2010, J. Cheminformatics.

[2]  Axel Drefahl,et al.  CurlySMILES: a chemical language to customize and annotate encodings of molecular and nanodevice structures , 2011, J. Cheminformatics.

[3]  A. Mankin,et al.  Nucleotide Biosynthesis Is Critical for Growth of Bacteria in Human Blood , 2008, PLoS pathogens.

[4]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[5]  Adamandia Kapopoulou,et al.  TubercuList--10 years after. , 2011, Tuberculosis.

[6]  A. Sali,et al.  Statistical potential for assessment and prediction of protein structures , 2006, Protein science : a publication of the Protein Society.

[7]  M. Billingsley.  Druggable Targets and Targeted Drugs: Enhancing the Development of New Therapeutics , 2008, Pharmacology.

[8]  M J Sippl,et al.  Knowledge-based potentials for proteins. , 1995, Current opinion in structural biology.

[9]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[10]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[11]  John P. Overington,et al.  Genomic-scale prioritization of drug targets: the TDR Targets database , 2008, Nature Reviews Drug Discovery.

[12]  James R. Brown,et al.  Identification of gene targets against dormant phase Mycobacterium tuberculosis infections , 2007, BMC infectious diseases.

[13]  David Eisenberg,et al.  Structural genomics of Mycobacterium tuberculosis: a preliminary report of progress at UCLA. , 2003, Biophysical chemistry.

[14]  S. Datta,et al.  Polyphosphate Kinase from M. tuberculosis: An Interconnect between the Genetic and Biochemical Role , 2010, PloS one.

[15]  Noel M. O'Boyle,et al.  De novo design of molecular wires with optimal properties for solar energy conversion , 2011, Journal of Cheminformatics.

[16]  M. Sippl.  Recognition of errors in three‐dimensional structures of proteins , 1993, Proteins.

[17]  David S. Roos,et al.  Identification of Attractive Drug Targets in Neglected-Disease Pathogens Using an In Silico Approach , 2010, PLoS neglected tropical diseases.

[18]  Ying Zhang,et al.  Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus , 1996, Nature Medicine.

[19]  S. Sardari,et al.  An in Silico Approach for Prioritizing Drug Targets in Metabolic Pathway of Mycobacterium Tuberculosis , 2011 .

[20]  Mark D'Souza,et al.  From Genetic Footprinting to Antimicrobial Drug Targets: Examples in Cofactor Biosynthetic Pathways , 2002, Journal of bacteriology.

[21]  Christian Stolte,et al.  TB database: an integrated platform for tuberculosis research , 2008, Nucleic Acids Res..

[22]  P. V. van Helden,et al.  Drug resistance in Mycobacterium tuberculosis. , 2006, Current issues in molecular biology.

[23]  Carsten Kutzner,et al.  GROMACS 4:  Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. , 2008, Journal of chemical theory and computation.

[24]  E. Rubin,et al.  Genes required for mycobacterial growth defined by high density mutagenesis , 2003, Molecular microbiology.

[25]  Narayanan Eswar,et al.  Protein structure modeling with MODELLER. , 2008, Methods in molecular biology.

[26]  E. Myers,et al.  Basic local alignment search tool. , 1990, Journal of molecular biology.

[27]  中尾 光輝,et al.  KEGG(Kyoto Encyclopedia of Genes and Genomes)〔和文〕 (特集 ゲノム医学の現在と未来--基礎と臨床) -- (データベース) , 2000 .

[28]  Manfred J. Sippl,et al.  Thirty years of environmental health research--and growing. , 1996, Nucleic Acids Res..

[29]  Arkady Mustaev,et al.  Structural Mechanism for Rifampicin Inhibition of Bacterial RNA Polymerase , 2001, Cell.

[30]  Martin Ester,et al.  PSORTb 3.0: improved protein subcellular localization prediction with refined localization subcategories and predictive capabilities for all prokaryotes , 2010, Bioinform..

[31]  T. Yeates,et al.  Verification of protein structures: Patterns of nonbonded atomic interactions , 1993, Protein science : a publication of the Protein Society.

[32]  T. A. Venkitasubramanian,et al.  Metabolism of mycobacteria , 1985, Journal of Biosciences.

[33]  Audrey S. M. Teo,et al.  Novel Mutations in ndh in Isoniazid-Resistant Mycobacterium tuberculosisIsolates , 2001, Antimicrobial Agents and Chemotherapy.

[34]  Samiul Hasan,et al.  Prioritizing Genomic Drug Targets in Pathogens: Application to Mycobacterium tuberculosis , 2006, PLoS Comput. Biol..

[35]  G J Williams,et al.  The Protein Data Bank: a computer-based archival file for macromolecular structures. , 1978, Archives of biochemistry and biophysics.

[36]  L. A. Basso,et al.  The Rv1712 Locus from Mycobacterium tuberculosis H37Rv Codes for a Functional CMP Kinase That Preferentially Phosphorylates dCMP , 2009, Journal of bacteriology.

[37]  S. Jhamb,et al.  Models of Latent Tuberculosis: Their Salient Features, Limitations, and Development , 2011, Journal of laboratory physicians.

[38]  I. Charles,et al.  Structure of Staphylococcus aureus cytidine monophosphate kinase in complex with cytidine 5′-monophosphate , 2006, Acta crystallographica. Section F, Structural biology and crystallization communications.

[39]  Karl W. Broman,et al.  A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: Application to Mycobacterium tuberculosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Judith G. Moore,et al.  Interactive Plotting Program , 1988 .

[41]  Budhayash Gautam,et al.  Metabolic pathway analysis and molecular docking analysis for identification of putative drug targets in Toxoplasma gondii: novel approach , 2012, Bioinformation.

[42]  J Andrew McCammon,et al.  BINANA: a novel algorithm for ligand-binding characterization. , 2011, Journal of molecular graphics & modelling.

[43]  L. Tanoue.  Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa , 2008 .

[44]  Max Salfinger,et al.  The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis , 2001, Respiratory research.

[45]  L. Rajendran,et al.  Subcellular targeting strategies for drug design and delivery , 2010, Nature Reviews Drug Discovery.

[46]  D. Russell.  Phagosomes, fatty acids and tuberculosis , 2003, Nature Cell Biology.

[47]  L. A. Basso,et al.  Molecular modeling and dynamics studies of cytidylate kinase from Mycobacterium tuberculosis H37Rv , 2008, Journal of molecular modeling.

[48]  Qiang Huang,et al.  A novel inhibitor of indole‐3‐glycerol phosphate synthase with activity against multidrug‐resistant Mycobacterium tuberculosis , 2009, The FEBS journal.

[49]  Chris Morley,et al.  Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.

[50]  Sharmila Anishetty,et al.  Potential drug targets in Mycobacterium tuberculosis through metabolic pathway analysis , 2005, Comput. Biol. Chem..